NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Voyager Therapeutics, Inc. (VYGR) Stock Analysis

Voyager Therapeutics, Inc. (VYGR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

VYGR

$2.02

−$0.17 (−7.76%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VYGR with… →

VYGR Key Statistics

As of Oct 21, 2026
Trading
Open
$2.02
Previous Close
$2.19
Day's Range
1.97–2.16
52-Week Range
1.89–5.48
Volume
934.79K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.28
Valuation
Market Cap
$124.47M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.61
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.81
Financials (FY)
Revenue (FY)
$40.37M−49.53%
Net Income (FY)
−$119.72M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
61.62M
1-Year Return
−59.36%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
596.16K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, VYGR closed at $2.02, −59.36% over 1 year.

Voyager Therapeutics, Inc. (VYGR) has a market capitalization of $124.47M.

In fiscal 2025, VYGR reported revenue of $40.37M.

VYGR Stock Return by Calendar Year

Voyager Therapeutics, Inc. (VYGR) 10-year return: what $10,000 became

1 year
$10,000 $4,064
−59.36%
5 years
$10,000 $5,166
−48.34%
10 years
$10,000 $1,622
−83.78%

If you had invested $10,000 in Voyager Therapeutics, Inc. (VYGR) 10 years ago, at the close on October 21, 2016, it would have been worth $1,622 at the close on October 21, 2026: −83.78% in total, −16.63% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−48.60%
2025−30.69%
2024−32.82%
2023+38.36%
2022+125.09%
2021−62.10%
2020−48.75%
2019+48.40%
2018−43.37%
2017+30.30%
2016 (partial year)−21.65%

As of October 21, 2026.

VYGR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$40.37M−$119.72M−296.5%
2024$80.00M−$65.00M−81.3%
2023$250.01M$132.33M52.9%
2022$40.91M−$46.41M−113.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$40.37M—−$131.84M−$119.72M−296.5%
2024$80.00M—−$83.29M−$65.00M−81.3%
2023$250.01M—$122.01M$132.33M52.9%
2022$40.91M—−$50.84M−$46.41M−113.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

VYGR Valuation vs Biotechnology Median

Median of 608 stocks
MetricVYGRBiotechnology medianvs median
P/S ratio3.6113.300.3x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Voyager Therapeutics, Inc. (VYGR) is capitalised at $124.47M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 141 employees.

The 52-week range on file runs from $1.89 to $5.48. VYGR last closed at $2.02 on October 21, 2026. That is −$0.17 (−7.76%) against the previous close. The latest close sits 6.88% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $40.37M. Against the prior fiscal year total of $80.00M, that is a change of −49.53%. The same year closed with a net loss of $119.72M. Earnings per share on a trailing basis come to −1.81.

Across the 4 fiscal years on file, revenue moves from $40.91M in 2022 to $40.37M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 3.61. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −59.36%. Measured over 10 years, that is −16.63% a year compounded. The reported beta is 1.28. Daily returns over the trailing 10 years annualize to a volatility of 75.68%.

Growth & Income

No dividend is on file for VYGR.

Across the complete calendar years on file, 2022 returned +125.09% and 2021 returned −62.10%. Of the 9 complete calendar years on file, 4 finished higher. 2026 is still running; the total return is −48.60% year to date.

Peer Comparison

Voyager Therapeutics, Inc. (VYGR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Voyager Therapeutics, Inc. VYGR $124.47M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Voyager Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Visit website →